Orthometrix's shock wave therapy:
This article was originally published in Clinica
Executive Summary
The US FDA has given Orthometrix approval to market its high-energy shock wave system for relieving chronic plantar fasciitis (foot pain). The Orbasone device, a small and compact product, creates shock waves by using a spark plug enclosed in a soft membrane-covered dome filled with water; the dome is placed against the heel. The physician-supervised treatment typically takes about 30-40 minutes. The American Podiatric Medical Association in 2000 said that 38.6 million people in the US suffered from plantar fasciitis, noted the White Plains, New York-based firm. The Orbasone system is already cleared for sale in Europe, Asia and Canada.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.